Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Plummer R, Vidal L, Griffin M, Lesley M, de Bono J, Coulthard S, Sludden J, Siu LL, Chen EX, Oza AM, Reid GK, McLeod AR, Besterman JM, Lee C, Judson I, Calvert H, Boddy AV.
Plummer R, et al. Among authors: chen ex.
Clin Cancer Res. 2009 May 1;15(9):3177-83. doi: 10.1158/1078-0432.CCR-08-2859. Epub 2009 Apr 21.
Clin Cancer Res. 2009.
PMID: 19383817
Free article.
Clinical Trial.